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cans [54%] (p < 0.05). Similarly, in patients with asthma, we
found that African American patients were 65% less likely to
have the recommended medication possession rate of at least
80% [RR: 0.35, 95% CI: 0.15–0.81]. There were no signiﬁcant
patient differentials in controller medication adherence by race
in patients with psoriasis.
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OBJECTIVES: To assess the impact of polypharmacy inter-
vention on drug cost in the Medicare Part D population.
METHODS: This is a case-control study, based on 2006
Medicare Part D population. The case group contains cases
which have received Polypharmacy interventions, whereas the
control group contains cases which have not been intervened
upon. Per member per month (PMPM) drug savings were cal-
culated as the difference between the projected post-intervention
drug cost of the case group and the actual post-intervention drug
cost of the case group. The projected post-intervention drug cost
is based on the pre-post intervention percent change in the
PMPM drug cost of the control group. RESULTS: There were
6050 Polypharmacy cases, of which 3442 were intervened on.
The remainder served as the control group. The actual post-inter-
vention PMPM drug cost for the case group was $611 and the
projected post-intervention PMPM drug cost for the same group
was $663, a difference of $52, representing $52 PMPM drug
cost savings. CONCLUSION: Polypharmacy MTMP may not
only help improve therapeutic outcomes through improved med-
ication use, but may also reduce overall health cost. The present
study showed signiﬁcant pharmacy savings as a result of
Polypharmacy intervention. This study did not address medical
cost savings due to the lack of longitudinal medical claim data.
However it would not be unreasonable to assume Polypharmacy
intervention could signiﬁcantly reduce medical cost.
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OBJECTIVES: State Medicaid programs vary drastically in terms
of their prescription drug expenditure per recipient. Prior research
has attempted to explain these variations by identifying potential
determinants of drug expenditure. However, analyses in the past
have been restricted to a few variables and several other poten-
tial determinants and their interactions have not been investi-
gated. Objectives of this study were: a) To identify potential
determinants of Medicaid per capita drug expenditures based on
an established comprehensive model for health services utiliza-
tion; and b) to test impacts of the identiﬁed determinants on per
capita drug expenditures. METHODS: This study employs
Andersen’s Behavior Model of Health Services Utilization to iden-
tify potential determinants of pharmaceutical expenditures in
state Medicaid programs using publicly available data. A struc-
ture equation model was built to test relationships among the
latent constructs of policy, access, predisposing characteristics,
enabling resources, and need for health care, and their inﬂuence
on drug utilization. RESULTS: “Predisposing characteristics”
were found to impact “enabling resources” which, in turn, was
found to signiﬁcantly impact drug utilization. Among the
observed variables, “access to hospitals” and “access to primary
care physicians” signiﬁcantly described “health care resources”;
“risk of diseases” described “need for health care”; and “poverty”
described the latent construct of “enabling resources”. The
“policy” construct was not described adequately by the indica-
tor variables. CONCLUSION: Based on the study results, we con-
clude that Medicaid policy and program interventions, as
described in this model, do not inﬂuence drug costs signiﬁcantly.
Population characteristics like predispositions and enabling
resources determine drug costs in the state Medicaid programs.
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OBJECTIVES: To examine the impact of consumer driven health
plans (CDHPs) on pharmacy and medical utilization, health care
and pharmacy expenditures. METHODS: We utilized enroll-
ment, medical and pharmacy claims data from a national
employer who switched from offering a traditional PPO based
plan (i.e., the “pre” period in 2004) to only offering CDHP
options to their employees in 2005 (i.e., the “post” period).
Patients with select chronic diseases including diabetes and
asthma were included for analyses. Outcomes measured included
total number of prescriptions, disease based medication adher-
ence (estimated by the Medication Possession Ratio (MPR) with
80% or higher classiﬁed as being “adherent”), ER, inpatient and
outpatient visits and pharmacy and health care expenditures.
GEE (Generalized Estimating Equations) for repeated measures
were used because there are 2 correlated observations on each
subject in the dataset adjusting for age, gender, co-morbid risk
scores, family size, coverage status and migration patterns
between the CDHP options. Outcomes variables that were char-
acterized by a large proportion of 0s and extreme right skew
were analyzed using two-part models with logarithmic transfor-
mation of the non-zero observations and a smearing re-trans-
formation. RESULTS: Preliminary results show that for CDHP
switchers there was a reduction in most measures: outpatient
visits reduced by 22%, total number of prescriptions decreased
by 25%, medical and pharmacy expenditures reduced by 22%
and 24% respectively. Individuals were 37% less likely to be
adherent with their drug therapy across all disease states in a
CDHP compared to their adherence in a PPO plan. There were
no appreciable differences in ER and inpatient visits. CON-
CLUSION: Switching to a CDHP resulted in lower utilization of
some services and expenditures. Switching was also associated
with decrease inﬂuenced by CDHP beneﬁt design. CDHPs can
be a useful plan offering but plans should design interventions
to improve medication adherence.
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